| Literature DB >> 24506881 |
Michael Mendicino1, Alexander M Bailey2, Keith Wonnacott3, Raj K Puri3, Steven R Bauer4.
Abstract
Proposals submitted to the FDA for MSC-based products are undergoing a rapid expansion that is characterized by increased variability in donor and tissue sources, manufacturing processes, proposed functional mechanisms, and characterization methods. Here we discuss the diversity in MSC-based clinical trial product proposals and highlight potential challenges for clinical translation.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24506881 DOI： 10.1016/j.stem.2014.01.013
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633